A5066653118- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Receptor Mechanisms and Signaling
- Blood Pressure and Hypertension Studies
- Nitric Oxide and Endothelin Effects
- Hormonal Regulation and Hypertension
- Neurotransmitter Receptor Influence on Behavior
- Neuropeptides and Animal Physiology
- Antiplatelet Therapy and Cardiovascular Diseases
- Pharmaceutical Economics and Policy
- Heart Rate Variability and Autonomic Control
- Cancer, Lipids, and Metabolism
- Neuroscience and Neuropharmacology Research
- Computational Drug Discovery Methods
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Ion channel regulation and function
- Sodium Intake and Health
- Cardiac, Anesthesia and Surgical Outcomes
- Coronary Interventions and Diagnostics
- Atherosclerosis and Cardiovascular Diseases
- Adipose Tissue and Metabolism
- Metabolomics and Mass Spectrometry Studies
- Heart Failure Treatment and Management
- Hormonal and reproductive studies
- Peptidase Inhibition and Analysis
Imperial College London
2016-2025
Lung Institute
1999-2022
Brigham and Women's Hospital
2021
St Mary's Hospital
1989-2018
University of Dundee
2016
The University of Texas Health Science Center at Houston
2016
Amsterdam UMC Location University of Amsterdam
2016
Hammersmith Hospital
2016
Sorbonne Université
2004
Pitié-Salpêtrière Hospital
2004
Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels low-density lipoprotein (LDL) cholesterol result their use are associated with cognitive deficits. Methods In a subgroup patients randomized, placebo-controlled trial evolocumab added statin therapy, we prospectively assessed function using Cambridge Neuropsychological Test Automated Battery. The primary end point was score on...
Background and Purpose— The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5–1.2) mmol/L significantly reduced major vascular events in the FOURIER trial (Further Cardiovascular Outcomes Research with Inhibition Subjects Elevated Risk). Herein, we report results of a prespecified analysis cerebrovascular overall population patients stratified prior stroke. Methods— was randomized,...
Abstract Background and Aims Visit-to-visit systolic blood pressure variability (BPV) is an important predictor of cardiovascular (CV) outcomes. The long-term effect a period (BP) control, but with differential BPV, uncertain. Morbidity mortality follow-up UK participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to 21 years determine CV impact mean (SBP) control BPV during trial, amongst those allocated amlodipine- atenolol-based...
<b>Objective</b> To assess if very elderly people with hypertension obtain early benefit from antihypertensive treatment. <b>Design</b> One year open label active treatment extension of randomised controlled trial (Hypertension in the Very Elderly Trial (HYVET)). <b>Setting</b> Hospital and general practice based centres mainly eastern western Europe, China, Tunisia. <b>Participants</b> People on double blind at end HYVET were eligible to enter extension. <b>Interventions</b> Participants...
The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been demonstrated to reduce the composite of myocardial infarction, stroke, or cardiovascular death in patients with established atherosclerotic disease. To our knowledge, long-term cost-effectiveness this therapy not evaluated using clinical trial efficacy data.To evaluate disease when added standard background therapy.A Markov cohort state-transition model was used, integrating US population-specific demographics,...
Recent studies have shown that Friedewald underestimates low-density lipoprotein cholesterol (LDL-C) at lower levels, which could result in undertreatment of high-risk patients. A novel method (Martin/Hopkins) using a patient-specific conversion factor provides more accurate LDL-C levels. However, this has not been tested proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor-treated patients.To investigate accuracy 2 different methods for estimating levels (Martin/Hopkins and...
Some trials have reported diminished efficacy for statins in the elderly, and women compared with men. We examined safety of evolocumab by patient age sex FOURIER trial, first major cardiovascular outcome trial a PCSK9 inhibitor.FOURIER was randomised, double blind comparing placebo 27,564 patients atherosclerotic disease receiving statin therapy (median follow-up 2.2 years). The primary endpoint death, myocardial infarction, stroke, hospitalisation unstable angina or coronary...
Some studies have suggested a link between antihypertensive medication and cancer, but the evidence is so far inconclusive. Thus, we aimed to investigate this association in large individual patient data meta-analysis of randomised clinical trials.
Background Identifying the mechanistic pathways potentially associated with incident heart failure (HF) may provide a basis for novel preventive strategies. Methods and Results To identify proteomic biomarkers potential underlying that be HF defined as first hospitalization HF, nested-matched case-control design was used cases (incident HF) controls (without selected from 3 cohorts (>20 000 individuals). Controls were matched on cohort, follow-up time, age, sex. Two independent sample sets...
Journal Article CARDIOVASCULAR REFLEXES AND BIOCHEMICAL RESPONSES IN PROGRESSIVE AUTONOMIC FAILURE Get access ROGER BANNISTER, BANNISTER National Hospital for Nervous Diseases, Queen Square, London, WC2 and St. Mary's Medical Unit, W2 Search other works by this author on: Oxford Academic PubMed Google Scholar PETER SEVER, SEVER MAURICE GROSS Brain, Volume 100, Issue 2, 1977, Pages 327–344, https://doi.org/10.1093/brain/100.2.327 Published: 01 April 1977 history Received: 15 September 1976
Recent guidelines have recommended nonfasting for routine testing of lipid levels based on comparisons and fasting populations. However, no previous study has examined the association cardiovascular outcomes with vs measured in same individuals.
In 62 untreated patients with essential hypertension, arterial baroreflex sensitivity (BRS) for heart rate, i.e. the change in pulse interval response to a phenylephrine-induced increase blood pressure, was compared (1) haemodynamic changes during mental arithmetic, reaction time test, isometric and bicycle exercise; (2) plasma noradrenaline (PNA) concentrations at rest, exercise and; (3) variability of ambulatory intra-arterial pressure. Subjects diminished BRS showed following responses:...
1. The role of the endothelium in mediating relaxation to acetylcholine, calcium ionophore A23187, vasoactive intestinal peptide and histidine methionine was studied using isolated human blood vessels. 2. Segments renal, colic, pulmonary, uterine, transverse cervical, brachial, coronary coeliac branch arteries, saphenous veins, were obtained from surgical resection material for use tissue bath studies. 3. Acetylcholine or A23187 produced endothelium-dependent vessels all vascular beds...
Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. Similar questions were regarding proprotein convertase subtilisin/kexin‐type 9 inhibitors ( PCSK9i ) neurocognitive function. No prospectively designed study has evaluated the relationship between long‐term use cognition changes. Patients with prior cardiovascular disease treated maximally tolerated statin enrolled in FOURIER (the randomized, double‐blind,...
<h3>Importance</h3> Little is known about the heterogeneity in low-density lipoprotein cholesterol levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor medications. <h3>Objective</h3> To evaluate interindividual variability LDL-C reduction PCSK9 drug evolocumab. <h3>Design, Setting, and Participants</h3> We examined percentage change from baseline Further Cardiovascular Outcomes Research With Inhibition Subjects Elevated Risk (FOURIER) trial, a...